PSA Screening Lowers Mortality, Analysis of Clinical Trials Concludes

PSA Screening Lowers Mortality, Analysis of Clinical Trials Concludes
Prostate cancer screening using prostate-specific antigen (PSA) does reduce mortality in prostate cancer, according to a review that used a new approach to analyze data from large clinical trials. The findings suggest that current recommendations, which advise against PSA-based screening, might need to be revised, researchers write in their report, which was published in the journal Annals of Internal Medicine. Interestingly, the study, “Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials,” used the same source data
Subscribe or to access all post and page content.

One comment

  1. cl dickinson says:

    Since I HAD prostate cancer (and a “focal procedure” to remove tumors) AND I am on testosterone replacement therapy, one would THINK that medicare might pay for a PSA test. Nope…. I’m on my second appeal now… (seems they are willing to gamble $114 a year against tens of thousands for my care if it comes back and I’m hospitalized)…
    Thats Government run “healthcare” for you

Leave a Comment

Your email address will not be published. Required fields are marked *